Enrollment Status and Trial Design

The NCT04609046 trial, sponsored by the National Cancer Institute (NCI) and conducted by the Alliance for Clinical Trials in Oncology, is a Phase 1 study enrolling 47 patients with newly diagnosed primary central nervous system (CNS) lymphoma. Treatment began on May 24, 2021, and enrollment is ongoing with a renewal deadline of June 30, 2026. The primary completion and study end dates are set for April 1, 2027. Induction therapy consists of up to six cycles in a 14-day cycle, and maintenance therapy consists of up to 12 cycles in a 28-day cycle. The primary endpoint is the maximum tolerated dose (MTD) of lenalidomide and the proportion of patients continuing lenalidomide or nivolumab maintenance therapy for six months after induction.

Combination of Four Mechanisms

Nivo-MR2 combines rituximab (Rituxan, CD20-targeting), high-dose methotrexate (DHFR inhibition), lenalidomide (Revlimid, cereblon-binding), and nivolumab (Opdivo, PD-1 blocking). Rituximab eliminates CD20-positive B cells, methotrexate reaches the CNS and inhibits DNA synthesis, lenalidomide induces cereblon-mediated proteolysis and immune modulation, and nivolumab blocks PD-1 and PD-L1/PD-L2 interactions to restore anti-tumor T-cell responses. Therefore, this is not a simple anti-angiogenic combination but a dose-escalation study targeting tumor cell elimination, cytotoxic chemotherapy, and modulation of the tumor microenvironment simultaneously.

Standard of Care and Competitive Landscape

The standard of care for primary CNS lymphoma is high-dose methotrexate, with competitive induction therapies including MATRix and R-MPV. MATRix, a combination of methotrexate, cytarabine, rituximab, and thiotepa, achieved an overall survival rate of 56% in long-term follow-up of a randomized study, outperforming 21% for two-drug regimens and 37% for three-drug regimens. R-MPV, a combination of rituximab, methotrexate, procarbazine, and vincristine, showed an objective response rate of 97% and a complete response rate of 66% in a Phase 2 trial. Nivo-MR2 is not directly compared to these strong induction therapies, so its current value lies in elucidating the tolerability and feasibility of long-term maintenance therapy with the four-drug combination, rather than demonstrating efficacy superiority.

Regulatory and Market Implications

Lenalidomide was first FDA approved on December 27, 2005, nivolumab on December 22, 2014, and rituximab on November 26, 1997. However, the Nivo-MR2 combination for primary CNS lymphoma is in Phase 1 development. There is no regulatory submission or FDA Advisory Committee (AdComm) voting stage for this indication, and clinical trial results have not yet been published. The global CNS lymphoma market is projected to grow from USD 1.53 billion in 2025 to USD 1.63 billion in 2026, representing a high-intensity treatment market with significant hospitalization burdens despite its orphan disease status. Success could provide Bristol Myers Squibb (BMY) with lenalidomide and nivolumab, and Roche Holding (RHHBY) with Genentech's rituximab, with clinical evidence to expand their existing approvals into CNS hematologic maintenance therapy.